MassDevice reports on the case of a US Army Cardiologist forced to repay illegal payments from Boston Scientific
Boston Scientific
Boston Scientific Launches Coyote™ Balloon Catheter
Ultra-low profile, highly deliverable balloon dilatation catheter offers physicians exceptional performance in peripheral angioplasty procedures
Boston Scientific Begins Enrolment in NECTAR-HF Clinical Trial
Boston Scientific commences study designed to assess preliminary safety and efficacy of chronic vagal nerve stimulation in heart failure patients
Clinical Data Demonstrates Long Term Safety of Boston Scientific’s Alair[TM]Bronchial Thermoplasty System
Five-year data from Research in Severe Asthma (RISA) Trial demonstrate maintenance of stable lung function and absence of late clinical complications. Patients in Europe with severe asthma can now benefit from unique and proven non-drug therapy.
J&J and Boston Scientific: Mahoney’s unusual employment contract
Wall Street Journal has uncovered an unusual contractual arrangement for Michael Mahoney as he returns to Boston Scientific
European Society of Cardiology reports lower rate of stent thrombosis with second-generation drug-eluting stent.sults of the EXAMINATION trial nt drug coating beats Boston Scientific’s Taxus DES
Lower rate of stent thrombosis found with second-generation drug-eluting stent than with bare metal stent: results of the EXAMINATION trial
FDA may revoke 510(k) clearances for transvaginal mesh products
Recent warnings and pressure from public groups may see transvaginal mesh devices bumped up to a higher risk FDA classification.
Jury awards Boston Scientific $19.5M in Cordis patent case
Boston Scientific Corp. said Thursday that a District Court jury in Delaware found that Cordis Corp., the stent-making unit of … continue reading “Jury awards Boston Scientific $19.5M in Cordis patent case”
Boston Scientific Corporation announces two-year data from its SYNTAX clinical trial
Two-Year SYNTAX Data Show Comparable Safety Outcomes for Complex Patients Treated With TAXUS® EXPRESS® Stents and Bypass Surgery.
Boston Scientific Corporation announces long-term data from the Prevention of Sudden Cardiac Death II registry (PreSCD II)
Boston Scientific Corporation’s PreSCD II Registry Shows ICDs Lead to 44 Percent Reduction in Mortality for Heart Attack Survivors.
Boston Scientific Names Leading Electrophysiologist to Its Medical Team
Boston Scientific Corporation today announced that Ken Stein, M.D., FACC, will join the Company as Senior Vice President and Associate Chief Medical Officer for its Cardiac Rhythm Management group.
Boston Scientific Announces CEO Change
Boston Scientific Corporation announced today that President and Chief Executive Officer Jim Tobin will retire from the Company, and that Ray Elliott has been appointed the new President and CEO.
FDA Clears Boston Scientific’s SpyScope® Access and Delivery Catheter
Boston Scientific Corporation today announced that it has received FDA 510(k) clearance to market its SpyScope® Access and Delivery Catheter for diagnostic and therapeutic applications in the pancreatico-biliary system.
FDA Approves Boston Scientific’s Next-Generation TAXUS® Liberte® Atom™ Stent System
Boston Scientific Corporation today announced it has received approval from the U.S. Food and Drug Administration to market its TAXUS® Liberte® Atom™ Paclitaxel-Eluting Coronary Stent System.
Boston Scientific Announces Changes to Board of Directors
Boston Scientific today announced that Ursula Burns and Kristina Johnson have resigned from the Company’s Board of Directors after accepting appointments in industry and government, respectively.
Boston Scientific Welcomes Results of Brain Aneurysm Clinical Trial
Boston Scientific Corporation today welcomed publication of results from the ISAT clinical trial showing patients with a ruptured intracranial aneurysm treated with endovascular coil embolization are 23 percent less likely to die within five years compared to patients who undergo surgical clipping.